{"url_path":"/sec/gri/8-k/2026-05-14/item-9-01","section_key":"item-9-01","section_title":"Item 9.01 Financial Statements and Exhibits.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-05-14","source_url":"https://www.sec.gov/Archives/edgar/data/1824293/0001824293-26-000046-index.html","accession_number":"0001824293-26-000046","cik":"0001824293","ticker":"GRI","issuer_name":"GRI Bio, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1824293/0001824293-26-000046-index.html","primary_entity_key":"0001824293","primary_entity_name":"GRI Bio, Inc."},"word_count":80,"has_tables":true,"body_markdown":"Item 9.01 Financial Statements and Exhibits.\n\n(d) Exhibits\n\nExhibit No. Description\n\n99.1\n[Press Release issued by GRI Bio, Inc., dated May 14, 2026.](ex991_pressreleaseq126earn.htm)\n\n104Cover Page Interactive Data File (embedded within the Inline XBRL document).\n\nSIGNATURES\n\nPursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.\n\nDate: May 14, 2026GRI Bio, Inc.\n\nBy: /s/ Leanne Kelly\n\nLeanne Kelly\n\nChief Financial Officer"}